
1. parasite. 2013;20:19. doi: 10.1051/parasite/2013020. epub 2013 may 27.

sulfadiazine resistance toxoplasma gondii: involvement overexpression or
polymorphisms genes therapeutic targets abc transporters.

doliwa c(1), escotte-binet s, aubert d, sauvage v, velard f, schmid a, villena i.

author information: 
(1)laboratoire de parasitologie-mycologie, ea 3800, sfr cap-santé fed 4231, ufr
médecine, université de reims champagne-ardenne, 51 rue cognacq-jay, 51095 reims 
cedex, france.

several treatment failures reported treatment toxoplasmic
encephalitis, chorioretinitis, congenital toxoplasmosis. recently found
three toxoplasma gondii strains naturally resistant sulfadiazine we
developed vitro two sulfadiazine resistant strains, rh-r(sdz) and
me-49-r(sdz), gradual pressure. plasmodium, common mechanisms drug
resistance involve, among others, mutations and/or amplification within genes
encoding therapeutic targets dhps dhfr and/or abc transporter genes
family. identify genotypic and/or phenotypic markers resistance t.
gondii, sequenced analyzed expression levels therapeutic targets
dhps dhfr, three abc genes, two pgp, tgabc.b1 tgabc.b2, one mrp,
tgabc.c1, sensitive strains compared sulfadiazine resistant strains.
neither polymorphism overexpression identified. contrary plasmodium,
in mutations and/or overexpression within gene targets abc transporters
are involved antimalarial resistance, t. gondii sulfadiazine resistance not
related toxoplasmic genes studied.

© c. doliwa et al., published edp sciences, 2013.

doi: 10.1051/parasite/2013020 
pmcid: pmc3718540
pmid: 23707894  [indexed medline]

